Global Neuropsychiatric Drugs Market

Report ID : 1170 | Published : 2021-07-28 | Pages: 140 | Format: PDF/EXCEL

The Global Market For Neuropsychiatric Drugs was valued at US$ 14,448.6 Mn in 2019 and recording an exponential CAGR of 4.2% during the period of 2019-2030.

Neuropsychiatric disorders are psychological disorder occur owing to a functional disturbance in the cerebral system. According to the National Institutes of Health, Neuropsychiatric disorders are one of the top 10 leading causes of global disability-adjusted life years (DALYs). The neuropsychiatry is concerned with illnesses of behavior and cognition that arise from evident disorder in cerebral function or indirect effects of the extracerebral disease. Among people age more than 65, neuropsychiatric is the most common disorder.  The rising prevalence of neuropsychiatric disorders globally and rising demand for advanced treatment are some of the key factors propelling the growth of the neuropsychiatric drugs market.

Psychiatric and neurological disorders are progressively important in society, mainly due to growing incidence rates of these disorders in adolescents and children and demographic changes. According to Leibniz Institute for Prevention Research and Epidemiology – BIPS, in 2015, about 38% of EU citizens, that is 165 million, suffered from a minimum of one disease from the neuropsychiatric range. Neuropsychiatric diseases are the key cause of impairment and disability of quality of life and capability to function. In Europe, more than 42% of years spent with a disability are attributed to neuropsychiatric disorders.

The Global Neuropsychiatric Drugs Market has a marvelous opportunity to grow during the estimated timeframe. The growing research and development activities for the development of novel treatment for neuropsychiatric disorders and the presence of a strong pipeline of these drugs are expected to propel the demand for neuropsychiatric disorder drugs during the forecast period. For instance, in January 2020, a clinical-stage biopharmaceutical company BlackThorn Therapeutics focused on evolving targeted drugs for the treatment of central nervous system (CNS) disorders has announced the progression of Phase 2 clinical trial for its BTRX-335140 (BTRX-140), a selective antagonist for the kappa opioid receptor (KOR). The introduction of advanced medicines for the treatment of neuropsychiatric disorders is estimated to propel the global demand for these drugs in the coming years.  Additionally, the growing demand for cost-effective drugs for neuropsychiatric disorders is expected to boost the demand for neuropsychiatric drugs during the forecast period. However, side effects such as blurred vision, drowsiness, and insomnia caused by these drugs may restrain the growth of the neuropsychiatric drugs market during the forecast period.

The Global Neuropsychiatric Drugs Market is segmented on the basis of drug type, indication, route of administration, and region. Based on the drug type, the market is divided into typical antipsychotics, and atypical antipsychotics. The typical antipsychotics include, Prochlorperazine, Haloperidol, and other drugs. Based on atypical antipsychotics, the market is segmented into, Aripiprazole, Asenapine, Cariprazine, Clozapine, Lurasidone, Olanzapine, Risperidone, and other drugs.  On the basis of indication, the market is categorized into bipolar disorder, schizophrenia, psychotic depression, and others. By route of administration, the neuropsychiatric drugs market is segmented into parenteral and oral route.  Based on region, the market is studied across Asia-Pacific, North America, LAMEA, and Europe. Among that, North America held the largest share of the market, followed by Europe in 2019. In terms of growth rate, Asia Pacific is expected to grow at a significant CAGR during the estimated timeframe.

The key players of this market include Novartis, Pfizer, Otsuka, Allergan, Eli Lilly, Sunovion, AstraZeneca, Actavis Laboratories, Johnson & Johnson, and Bristol Myers, Sage Therapeutics, BlackThorn Therapeutics, H. Lundbeck A/S, Takeda, Cerevel Therapeutics, LLC, among others.  The growing strategic partnership, merger among the key players operating in the market for the new drug development is expected to boost the market in the coming years.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Neuropsychiatric Drugs Market Snapshot

Chapter 4. Global Neuropsychiatric Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 2: By Drug Types Estimates & Trend Analysis

5.1. By Drug Types & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Drug Types:

5.2.1. Typical Antipsychotics

5.2.1.1.  Prochlorperazine

5.2.1.2.  Haloperidol

5.2.1.3.  Others

5.2.2. Atypical Antipsychotics

5.2.2.1.  Aripiprazole

5.2.2.2.  Asenapine

5.2.2.3.  Cariprazine

5.2.2.4.  Clozapine

5.2.2.5.  Lurasidone

5.2.2.6.  Olanzapine

5.2.2.7.  Risperidone

5.2.2.8.  Others

Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis

6.1. By Indications & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

6.2.1. Schizophrenia

6.2.2. Bipolar Disorder

6.2.3. Psychotic Depression

6.2.4. Other Indications

Chapter 7. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis

7.1. By Route of Administration & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Route of Administration:

7.2.1. Oral

7.2.2. Parenteral

Chapter 8. Neuropsychiatric Drugs Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts By Drug Types, 2020-2030

8.1.2. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2020-2030

8.1.3. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2020-2030

8.1.4. North America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

8.2. Europe

8.2.1. Europe Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, 2020-2030

8.2.2. Europe Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, 2020-2030

8.2.3. Europe Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2020-2030

8.2.4. Europe Neuropsychiatric Drugs Market revenue (US$ Million) by country, 2020-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, 2020-2030

8.3.2. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, 2020-2030

8.3.3. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2020-2030

8.3.4. Asia Pacific Neuropsychiatric Drugs Market revenue (US$ Million) by country, 2020-2030

8.4. Latin America

8.4.1. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, (US$ Million)

8.4.2. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, (US$ Million)

8.4.3. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2020-2030

8.4.4. Latin America Neuropsychiatric Drugs Market revenue (US$ Million) by country, (US$ Million) 2020-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) By Drug Types, (US$ Million)

8.5.2. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) By Indications, (US$ Million)

8.5.3. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2020-2030

8.5.4. Middle East & Africa Neuropsychiatric Drugs Market revenue (US$ Million) by country, (US$ Million) 2020-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Novartis

9.2.2. Pfizer

9.2.3. Otsuka

9.2.4. Allergan

9.2.5. Eli Lilly

9.2.6. Sunovion

9.2.7. AstraZeneca

9.2.8. Actavis Laboratories

9.2.9. Johnson & Johnson

9.2.10. Bristol Myers Squibb

9.2.11. Sage Therapeutics

9.2.12. BlackThorn Therapeutics

9.2.13. BioXcel Therapeutics

9.2.14. Lundbck A/S

9.2.15. Takeda

9.2.16. Cerevel Therapeutics, LLC

9.2.17. INmune Bio

9.2.18. Perception Neuroscience

9.2.19. Psilera Bioscience

9.2.20. Eleusis Holdings Ltd

9.2.21. Other Prominent Players

Global Neuropsychiatric Drugs Market Segmentation:

Global Neuropsychiatric Drugs Market by Drug Type

  • Typical Antipsychotics
    • Prochlorperazine
    • Haloperidol
    • Others
  • Atypical Antipsychotics
    • Aripiprazole
    • Asenapine
    • Cariprazine
    • Clozapine
    • Lurasidone
    • Olanzapine
    • Risperidone
    • Others

Global Neuropsychiatric Drugs Market Based on Indication

  • Schizophrenia
  • Bipolar Disorder
  • Psychotic Depression
  • Others

Global Neuropsychiatric Drugs Market Based on Route of Administration

  • Oral
  • Parenteral

Global Neuropsychiatric Drugs Market Based on Region

Europe Neuropsychiatric Drugs Market by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Neuropsychiatric Drugs Market by Country

  • U.S.
  • Canada

Asia Pacific Neuropsychiatric Drugs Market by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Neuropsychiatric Drugs Market by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Neuropsychiatric Drugs Market by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients